Serial measurement of WT1 expression and decrement ratio until hematopoietic cell transplantation as a marker of residual disease in patients with cytogenetically normal acute myelogenous leukemia

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 6, 2013, Pages 958-966

  Yoon, Jae Ho ^a   Kim, Hee Je ^a   Shin, Seung Hwan ^a   Yahng, Seung Ah ^a   Lee, Sung Eun ^a   Cho, Byung Sik ^a   Eom, Ki Seong ^a   Kim, Yoo Jin ^a   Lee, Seok ^a   Min, Chang Ki ^a   Cho, Seok Goo ^a   Kim, Dong Wook ^a   Lee, Jong Wook ^a   Min, Woo Sung ^a   Park, Chong Won ^a   Lim, Ji Hyang ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Acute myelogenous leukemia; FLT3 ITD; Normal karyotype; NPM1; WT1

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ENOCITABINE; ETOPOSIDE; FLT3 LIGAND; FLUDARABINE; IDARUBICIN; MELPHALAN; NUCLEOPHOSMIN; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CYTOGENETICS; DISEASE FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; WHOLE BODY RADIATION; WILD TYPE;

ADOLESCENT; ADULT; AGED; CYTOGENETIC ANALYSIS; FEMALE; GENE EXPRESSION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; NEOPLASM, RESIDUAL; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 84877903294     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.03.013     Document Type: Article

References (31)

1. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
2. Byrd J.C., Mrozek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
3. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
4. Baldus C.D., Thiede C., Soucek S., et al. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: Prognostic implications. J Clin Oncol 2006, 24:790-797.
5. Frohling S., Schlenk R.F., Breitruck J., et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 2002, 100:4372-4380.
6. Thiede C., Steudel C., Mohr B., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99:4326-4335.
7. Schnittger S., Schoch C., Kern W., et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005, 106:3733-3739.
8. Green C.L., Koo K.K., Hills R.K., et al. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: Impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 2010, 28:2739-2747.
9. Baldus C.D., Tanner S.M., Ruppert A.S., et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: A Cancer and Leukemia Group B Study. Blood 2003, 102:1613-1618.
10. Haferlach T., Kern W., Schoch C., et al. A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group. Haematologica 2004, 89:408-418.
11. Mrozek K., Marcucci G., Paschka P., et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: Are we ready for a prognostically prioritized molecular classification?. Blood 2007, 109:431-448.
12. Haber D.A., Buckler A.J., Glaser T., et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell 1990, 61:1257-1269.
13. Yang L., Han Y., Suarez Saiz F., Minden M.D. A tumor suppressor and oncogene: The WT1 story. Leukemia 2007, 21:868-876.
14. King-Underwood L., Pritchard-Jones K. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 1998, 91:2961-2968.
15. Paschka P., Marcucci G., Ruppert A.S., et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study. J Clin Oncol 2008, 26:4595-4602.
16. Gray J.X., McMillen L., Mollee P., et al. WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation. Leuk Res 2012, 36:453-458.
17. Cilloni D., Renneville A., Hermitte F., et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European Leukemia Net study. J Clin Oncol 2009, 27:5195-5201.
18. Weisser M., Kern W., Rauhut S., et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 2005, 19:1416-1423.
19. Lapillonne H., Renneville A., Auvrignon A., et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 2006, 24:1507-1515.
20. Kim Y.K., Kim H.N., Lee S.R., et al. Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia. Korean J Hematol 2010, 45:36-45.
21. Park S.H., Chi H.S., Min S.K., et al. Prognostic significance of the FLT3 ITD mutation in patients with normal-karyotype acute myeloid leukemia in relapse. Korean J Hematol 2011, 46:88-95.
22. Schneider F., Hoster E., Unterhalt M., et al. NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood 2009, 113:5250-5253.
23. Falini B., Mecucci C., Tiacci E., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005, 352:254-266.
24. Thiede C., Koch S., Creutzig E., et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006, 107:4011-4020.
25. Rollig C., Bornhauser M., Thiede C., et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European Leukemia Net recommendations: Evaluation of the proposed reporting system. J Clin Oncol 2011, 29:2758-2765.
26. Park H.S., Kim D.W., Kim C.C., et al. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: A newly designed induction regimen-a prospective, cooperative multicenter study. Semin Hematol 1996, 33:24-29.
27. Cilloni D., Gottardi E., Messa F., et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol 2003, 21:1988-1995.
28. Cilloni D., Gottardi E., De Micheli D., et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002, 16:2115-2121.
29. Najima Y., Ohashi K., Kawamura M., et al. Molecular monitoring of BAALC expression in patients with CD34-positive acute leukemia. Int J Hematol 2010, 91:636-645.
30. Cilloni D., Messa F., Arruga F., et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica 2008, 93:921-924.
31. Gaidzik V.I., Schlenk R.F., Moschny S., et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 2009, 113:4505-4511.